4.7 Review

Pediatric Pulmonary Hypertension

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 62, 期 25, 页码 D117-D126

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2013.10.028

关键词

congenital heart disease; pediatrics; pulmonary hypertension

资金

  1. Actelion
  2. Bayer
  3. Gilead
  4. Eli Lilly
  5. Pfizer
  6. United Therapeutics
  7. GlaxoSmithKline
  8. Lilly
  9. Novartis

向作者/读者索取更多资源

Pulmonary hypertension (PH) is a rare disease in newborns, infants, and children that is associated with significant morbidity and mortality. In the majority of pediatric patients, PH is idiopathic or associated with congenital heart disease and rarely is associated with other conditions such as connective tissue or thromboembolic disease. Incidence data from the Netherlands has revealed an annual incidence and point prevalence of 0.7 and 4.4 for idiopathic pulmonary arterial hypertension and 2.2 and 15.6 for pulmonary arterial hypertension, respectively, associated with congenital heart disease (CHD) cases per million children. The updated Nice classification for PH has been enhanced to include a greater depth of CHD and emphasizes persistent PH of the newborn and developmental lung diseases, such as bronchopulmonary dysplasia and congenital diaphragmatic hernia. The management of pediatric PH remains challenging because treatment decisions continue to depend largely on results from evidence-based adult studies and the clinical experience of pediatric experts. (C) 2013 by the American College of Cardiology Foundation

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据